Department of Dermatology and Maastricht University Center for Molecular Dermatology (MUCMD) and GROW - School for Oncology and Developmental Biology, Maastricht University Medical Center, P. Debyelaan 25; Postbus 5800, 6202 AZ Maastricht, The Netherlands
- Mots-clés : FH, Fumarate hydratase, MCUL, Multiple cutaneous and uterine leiomyomatosis syndrome, HLRCC, Hereditary leiomyomatosis and renal cell cancer, FHD, Fumarate hydratase deficiency, LOH, Loss of heterozygosity, RCC, Renal cell cancer, CRC, Collecting duct carcinoma, VHL, Von Hippel Lindau, VEGF, Vascular endothelial growth factor, PDGF, Platelet derived growth factor, EGFR, Endothelial growth factor receptor, Glut-1, Glucose transporter protein 1, TGF-α, Transforming growth factor-α
- DOI : 10.1684/ejd.2009.0749
- Page(s) : 545-51
- Année de parution : 2009
Multiple cutaneous and uterine leiomyomatosis syndrome (MCUL; OMIM 150800) is an autosomal dominantly inherited tumor predisposition disorder, characterized by leiomyomas of the skin and uterus. When associated with kidney cancer, this syndrome is known as hereditary leiomyomatosis and renal cell cancer (HLRCC; OMIM 605839). All disease variants result from heterozygous mutations in the fumarate hydratase (FH) gene. Cutaneous leiomyoma can easily be recognized and confirmed by histological examination. Recognition of these benign skin tumors can lead to the diagnosis of MCUL or HLRCC. Timely diagnosis is crucial for offering affected individuals and families potentially life-saving regular prophylactic screening examinations for renal tumors. Here we provide an overview of clinical and genetic features of this complex tumor syndrome and discuss patient management and current therapeutic strategies.